Martin joined the AMR Action Fund in August 2021 coming from Boehringer Ingelheim Venture Fund where he worked as Managing Director USA in Cambridge, MA. He served as board director of ArmaGen Technologies, Inc (acquired by JCR Pharma), Tilos Therapeutics Inc. (acquired by Merck & Co Inc.), Sentien Biotechnologies Inc., Abexxa Biologics Inc., Libra Therapeutics Inc. and Rgenta Therapeutics Inc. Martin also serves on the Board of Directors of MassBio.
Martin started his career at BayernKapital in the early 2000s to focus on seed investments in biotechnology companies in Germany. He held several Marketing positions at Solvay Pharmaceuticals and Boehringer Ingelheim in CNS and Oncology and was involved in the launch of various drugs in the CNS space.
Martin holds a PhD in Biology from University of Würzburg and an MBA from FernUniversität Hagen.